Professor, Head of Transplantation Biology Program Clinical Research Division, Fred Hutch

The Host of this webinar is Dr. Evarist Feliu.

Dr. Rainer Storb is one of the pioneers who established allogeneic, or donor, blood stem cell transplantation as a cure for diseases like leukemia and aplastic anemia. Over his career, his research has established more effective, less toxic transplant approaches. Through fundamental and translational research, he continues to explain and eliminate major barriers to successful transplant. These include rejection and failure of the transplanted cells and graft-vs.-host disease, or GVHD, and the discovery that grafted donor immune cells play a pivotal role in eliminating the patient’s malignant cells, a form of allogeneic immunotherapy. In GVHD, transplanted immune cells attack the patient’s healthy tissues. He is also working to reduce toxicities and maximize the cancer-killing powers of transplanted immune cells. One of Dr. Storb’s major scientific contributions is the non-myeloablative transplant. Non-myeloablative transplant, sometimes called "mini-transplant," involves minimal pre-transplant radiation. It has extended the lifesaving benefits of transplantation to older or more-infirm patients who are not eligible for traditional protocols.

IJC Auditorium + Online
Inscripció